Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xydocin is a veterinary fixed-dose combination antibiotic injection developed by Sarabhai Chemicals. It contains procaine penicillin G, penicillin G sodium, and streptomycin sulfate. This combination provides broad-spectrum antibacterial activity against mixed bacterial infections in livestock, such as cattle. Penicillin G (both procaine and sodium salts) acts by binding to and inactivating bacterial penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cell wall synthesis and causing cell lysis. Streptomycin sulfate, an aminoglycoside antibiotic, binds irreversibly to the bacterial 30S ribosomal subunit, leading to the misreading of mRNA and inhibition of protein synthesis. Xydocin is administered via intramuscular injection and is primarily indicated for mixed bacterial infections, mastitis, and pneumonia in livestock.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on procaine penicillin G + penicillin G sodium + streptomycin sulfate.